212 related articles for article (PubMed ID: 28399028)
1. Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
Bishop EA; Java JJ; Moore KN; Walker JL
Int J Gynecol Cancer; 2017 May; 27(4):730-737. PubMed ID: 28399028
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study.
Bishop EA; Java JJ; Moore KN; Spirtos NM; Pearl ML; Zivanovic O; Kushner DM; Backes F; Hamilton CA; Geller MA; Hurteau J; Mathews C; Wenham RM; Ramirez PT; Zweizig S; Walker JL
Am J Obstet Gynecol; 2018 Jan; 218(1):109.e1-109.e11. PubMed ID: 29037481
[TBL] [Abstract][Full Text] [Related]
3. A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer.
Song J; Le T; Hopkins L; Fung-Kee-Fung M; Lupe K; Gaudet M; E C; Samant R
Int J Gynecol Cancer; 2020 Feb; 30(2):160-166. PubMed ID: 31871112
[TBL] [Abstract][Full Text] [Related]
4. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
6. Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria.
Kong TW; Chang SJ; Paek J; Lee Y; Chun M; Ryu HS
J Gynecol Oncol; 2015 Jan; 26(1):32-9. PubMed ID: 25376915
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
8. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
9. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
Fader AN; Java J; Tenney M; Ricci S; Gunderson CC; Temkin SM; Spirtos N; Kushnir CL; Pearl ML; Zivanovic O; Tewari KS; O'Malley D; Hartenbach EM; Hamilton CA; Gould NS; Mannel RS; Rodgers W; Walker JL
Gynecol Oncol; 2016 Dec; 143(3):460-465. PubMed ID: 27743738
[TBL] [Abstract][Full Text] [Related]
10. The long-term survival of women with surgical stage II endometrioid type endometrial cancer.
Ayhan A; Taskiran C; Celik C; Yuce K
Gynecol Oncol; 2004 Apr; 93(1):9-13. PubMed ID: 15047207
[TBL] [Abstract][Full Text] [Related]
11. Assessing the effect of guideline introduction on clinical practice and outcome in patients with endometrial cancer in Japan: a project of the Japan Society of Gynecologic Oncology (JSGO) guideline evaluation committee.
Shigeta S; Nagase S; Mikami M; Ikeda M; Shida M; Sakaguchi I; Ushioda N; Takahashi F; Yamagami W; Yaegashi N; Udagawa Y; Katabuchi H
J Gynecol Oncol; 2017 Nov; 28(6):e76. PubMed ID: 29027394
[TBL] [Abstract][Full Text] [Related]
12. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
Plante M; Stanleigh J; Renaud MC; Sebastianelli A; Grondin K; Grégoire J
Gynecol Oncol; 2017 Aug; 146(2):240-246. PubMed ID: 28577885
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
[TBL] [Abstract][Full Text] [Related]
14. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study.
Fu HC; Chen JR; Chen MY; Hsu KF; Cheng WF; Chiang AJ; Ke YM; Chen YC; Chang YY; Huang CY; Kang CY; Kan YY; Hsiao SM; Yen MS
J Gynecol Oncol; 2018 Sep; 29(5):e76. PubMed ID: 30022636
[TBL] [Abstract][Full Text] [Related]
16. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma.
Yoon MS; Huh SJ; Kim HJ; Kim YS; Kim YB; Kim JY; Lee JH; Kim HJ; Cha J; Kim JH; Kim J; Yoon WS; Choi JH; Chun M; Choi Y; Lee KK; Kim M; Jeong JU; Chang SK; Park W
Cancer Res Treat; 2016 Jul; 48(3):1074-83. PubMed ID: 26511800
[TBL] [Abstract][Full Text] [Related]
18. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS; Cohn DE; Brasky TM; Zaino R; Park K; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Randall ME; Brinton LA
Am J Obstet Gynecol; 2018 Nov; 219(5):459.e1-459.e11. PubMed ID: 30096321
[TBL] [Abstract][Full Text] [Related]
19. Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?
Nugent EK; Bishop EA; Mathews CA; Moxley KM; Tenney M; Mannel RS; Walker JL; Moore KN; Landrum LM; McMeekin DS
Gynecol Oncol; 2012 Apr; 125(1):94-8. PubMed ID: 22155415
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
